



Oviduct Organoid Growth Media Kit - Human

709036

Instruction For Use

For Research Use Only
Store products at -25°C to -15°C

1. INTENDED USE

The Human Oviduct Organoid Growth Media Kit is intended for use by laboratory professionals to culture and grow organoids derived from normal and tumor tissues. Organoids are suspended within a basement membrane extract (BME) dome and surrounded by the organoid media. Media is replaced regularly to ensure availability of nutrients to, and removal of waste from, the organoids. For research use only, not for diagnostic or therapeutic use.

2. COMPONENTS

Part Number	Contents	Amount
700007	Base Media	1x 100mL Bottle
700008	Media Supplement	1x 4mL Vial

3. MEDIA PREPARATION

The base media and supplement are provided frozen and should remain frozen until use. Use aseptic technique to prepare the Oviduct Organoid Media.

1. Thaw the media and vial at room temperature (15-25°C) for several hours with periodic mixing, or overnight in a refrigerator (2-8°C).
2. Aseptically add the supplement vial to the base media and thoroughly mix.
3. Filter the combined media through a 0.2µm filter (not included) to a new bottle/tube.

4. STORAGE CONDITIONS AND SHELF LIFE

Media and supplement are stable for up to 6 months when frozen.

After thawing and mixing, the complete media is best used within 1 month when stored between 2-8°C.

5. REFERENCES

- [1] Asif, K., et. al. Iron nitroprusside as a chemodynamic agent and inducer of ferroptosis for ovarian cancer therapy. *J Mater. Chem. B*. 2023, 11, 3124. DOI: 10.1039/d2tb02691k
- [2] Scattolin, T., et. al. The anticancer activity of an air-stable Pd(I)-NHC (NHC = N-heterocyclic carbene) dimer. *Chem. Commun.*, 2020, 56, 12238. DOI: 10.1039/d0cc03883k
- [3] Tzouras, N. V., et. al. A Green Synthesis of Carbene-Metal-Amides (CMAs) and Carboline-Derived CMAs with Potent in vitro and ex vivo Anticancer Activity. *ChemMedChem.*, 2022, 17, DOI: 10.1002/cmdc.202200135
- [4] Granchi, C., et. al. Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors. *E. J. of MedChem.*, 2020, 209, 112857, DOI: 10.1016/j.ejmech.2020.112857

